Genmab to Participate in Upcoming Investor Conferences Media ReleaseCOPENHAGEN, Denmark; February 25, 2026 (Nasdaq: GMAB) announced today that members of its Executive Committee will participate in fireside chats at the following investor conferences in March 2026: TD Cowen 46th Annual Healthcare Conference in Boston on March 3, 2026, 9:10 AM EST (3:10 PM CET)Leerink Global Healthcare Conference in Miami on March 10, 2026, 8:40 AM EDT (1:40 PM CET)Barclays 28th Annual Global Healthcare Conference in Miami on March 11, 2026, 1:30 PM EDT (6:30 PM CET) The live and archived webcast of the p...
Major Shareholder Announcement Company Announcement Copenhagen, 25 February 2026No. 13/2026 Major Shareholder AnnouncementISS A/S, a leading workplace experience and facility management company, hereby announces that the company has received a notification pursuant to sections 39 and 40 of the Danish Capital Markets Act from Société Générale. Société Générale has notified the company that its direct or indirect aggregated holding of shares and financial instruments are below 5% of the total share capital and voting rights in ISS A/S. For investor enquiriesMichael Vitfell-Rasmussen, Head...
Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; February 24, 2026 – (Nasdaq: GMAB) will increase its share capital by 12,313 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 710 shares at DKK 1,147.50,239 shares at DKK 1,155.00,1,527 shares at DKK 1,161.00,1,183 shares at DKK 1,334.50,5,391 shares at DKK 1,362.50, and3...
Two Directors at ISS AS bought/maiden bought 3,700 shares at between 0.000DKK and 237.027DKK. The significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ove...
Acquisition of ISS A/S shares by Members of the Board of Directors Company Announcement Copenhagen, 24 February 2026 No. 12/2026 Acquisition of ISS A/S shares by Members of the Board of DirectorsISS A/S, a leading workplace experience and facility management company, has received notification pursuant to article 19 of the Market Abuse Regulation of transactions in ISS A/S’ shares made by pers...
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; February 23, 2026 – Genmab A/S (Nasdaq: GMAB). On February 17, 2026, Genmab announced the initiation of a share buy-back program to repurchase up to 342,130 shares with a maximum aggregate total value of DKK 725 million to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than March 31, 2026. The following transactions were executed under the program from February 18 to February 20, 2026: No. of sharesAverage price ...
Transactions in connection with share buyback programme Company Announcement Copenhagen, 23 February 2026No. 11/2026 Transactions in connection with share buyback programmeISS A/S, a leading workplace experience and facility management company, announced on 19 February 2026 a new share buyback programme, see company announcement no. 10/2026. The share buyback programme is executed in accordance Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 (the “Market Abuse Regulation”) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, al...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement COPENHAGEN, Denmark; February 20, 2026 – (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.